Overexpression of human epidermal growth factor receptor-2 (HER2) is reported in 25–30% of metastatic breast cancers, conferring to these tumours a more severe prognosis (Dean-Colomb and Esteva, 2008). The gene discussed is ERBB2; the disease is neoplasm.